{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-252475","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2026-06-02T11:05:16+00:00","discovered_at":"2026-06-02T11:10:00.234617+00:00","generated_at":"2026-06-02T11:11:26.547953+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026","bullets":["FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.","eGFR results now expected in the third quarter of 2026.","Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.","Alignment could accelerate path to full approval for atacicept."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252475","json":"https://secwatch.observer/filing/0001193125-26-252475.json","markdown":"https://secwatch.observer/filing/0001193125-26-252475.md","text":"https://secwatch.observer/filing/0001193125-26-252475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/0001193125-26-252475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:11:26.547953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-026760","ticker":"CING","company_name":"Cingulate Inc.","filed_at":"2026-06-02T12:10:25+00:00","headline":"Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026760","json":"https://secwatch.observer/filing/0001493152-26-026760.json","markdown":"https://secwatch.observer/filing/0001493152-26-026760.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/0001493152-26-026760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-252544","ticker":"MNKD","company_name":"MANNKIND CORP","filed_at":"2026-06-02T12:00:36+00:00","headline":"FDA approves Afrezza for pediatric diabetes patients ages 6+","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252544","json":"https://secwatch.observer/filing/0001193125-26-252544.json","markdown":"https://secwatch.observer/filing/0001193125-26-252544.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/0001193125-26-252544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/mnkd-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001108426-26-000030","ticker":"TXNM","company_name":"TXNM ENERGY INC","filed_at":"2026-06-01T21:54:12+00:00","headline":"TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108426-26-000030","json":"https://secwatch.observer/filing/0001108426-26-000030.json","markdown":"https://secwatch.observer/filing/0001108426-26-000030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108426/000110842626000030/0001108426-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/22767/000110842626000030/pnm-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251517","ticker":"LESL","company_name":"Leslie's, Inc.","filed_at":"2026-06-01T20:28:42+00:00","headline":"Leslie's regains Nasdaq compliance for minimum market value of publicly held shares","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251517","json":"https://secwatch.observer/filing/0001193125-26-251517.json","markdown":"https://secwatch.observer/filing/0001193125-26-251517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/0001193125-26-251517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/lesl-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068591","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-06-01T12:00:26+00:00","headline":"FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068591","json":"https://secwatch.observer/filing/0001104659-26-068591.json","markdown":"https://secwatch.observer/filing/0001104659-26-068591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/0001104659-26-068591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001476840-26-000050","ticker":"EXFY","company_name":"Expensify, Inc.","filed_at":"2026-05-29T21:15:09+00:00","headline":"Expensify regains Nasdaq minimum bid price compliance","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001476840-26-000050","json":"https://secwatch.observer/filing/0001476840-26-000050.json","markdown":"https://secwatch.observer/filing/0001476840-26-000050.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/0001476840-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/exfy-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001178913-26-002988","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-29T11:00:25+00:00","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","event_type":"regulatory","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002988","json":"https://secwatch.observer/filing/0001178913-26-002988.json","markdown":"https://secwatch.observer/filing/0001178913-26-002988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/0001178913-26-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}